Answers are grounded in this paper and cite their sources.
Background Accumulating evidence suggests that Hederagenin (HG) ameliorates pathological impairments in Alzheimer’s disease (AD), yet the underlying molecular mechanisms remain incompletely elucidated. This study aimed to investigate the therapeutic efficacy and potential molecular mechanisms of HG against AD. Methods Multiple public databases were utilized to screen putative targets of HG and AD. Bioinformatic approaches, including protein-protein interaction (PPI) network construction, GO/KEGG over-representation analyses, molecular docking (MD), and molecular dynamics simulations (MDS), were applied to predict the pharmacological mechanisms by which HG treats AD. Subsequent in vivo experiments using 5xFAD mice were performed to validate core targets. Biochemical indicators measured in this study included hippocampal p-AKT/AKT ratio, HIF-1α, GLUT1, IL-6, IL-1β, and IL-10 protein levels; behavioral tests were applied to evaluate cognitive performance. Results PPI network analysis identified interleukin-6 (IL-6) as the pivotal hub target associated with therapeutic effects of HG against AD. MD and MDS demonstrated moderate-to-favorable binding affinity (−7.517 kcal/mol) and acceptable conformational stability of the HG_IL-6 complex throughout the simulation. Thermal shift assays further provided preliminary biophysical evidence supporting physical interaction between HG and IL-6 protein. GO/KEGG enrichment analyses revealed that IL-6 was primarily enriched in inflammatory-response and glucose-homeostasis-related biological processes, with its downstream signaling cascades encompassing cancer-related pathways, the PI3K/Akt signaling pathway, and the HIF-1 signaling pathway. In-vivo data from 5xFAD mice showed that HG treatment markedly rescued cognitive deficits and alleviated pathological lesions. HG mitigated neuroinflammation and alters glucose-metabolism-associated protein markers via the PI3K/Akt/HIF-1 signaling pathway. Of note, co-administration of Resatorvid partially counteracted HG-mediated neuroprotective phenotypes in 5xFAD mice. Conclusion HG may exert neuroprotective effects in AD mice, and preliminary evidence suggests a potential interaction with IL-6. These neuroprotective phenotypes are associated with altered expression of neuroinflammatory and glucose-metabolism-related markers linked to the PI3K/Akt and HIF-1 signaling pathways. These findings offer novel mechanistic perspectives supporting HG as a promising candidate therapeutic agent for AD clinical translation.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: